Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
Rhea-AI Summary
Nexalin Technology (Nasdaq: NXL) invites investors to a live webinar on December 4, 2025 at 4:15 p.m. ET hosted by RedChip Companies.
CEO Mark White will discuss Nexalin’s proprietary non-invasive Deep Intracranial Frequency Stimulation (DIFS™), recent clinical collaborations including UC San Diego, the Gen-3 HALO™ Clarity headset, and a Virtual Clinic model for scalable at-home treatment. The company says it has secured regulatory approvals internationally while pursuing U.S. expansion and targets the $537 billion mental health market. Management will highlight patented technology, real-time AI-driven patient monitoring, and global footprint growth, followed by a live Q&A. Registration is free at the RedChip webinar page and questions can be pre-submitted to NXL@redchip.com.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus 1 Down
Momentum scanner shows only PTHL moving, down 4.11% with no news, while key peers like INBS, NVNO, AIMD, and ALUR show mixed modest gains. This points to stock-specific dynamics rather than a coordinated sector move around the webinar.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | FDA Q-Submission meeting | Positive | +1.6% | FDA Q-Submission meeting set framework for U.S. Alzheimer’s pilot study. |
| Dec 02 | Investor webinar invite | Positive | +5.4% | Announced investor webinar on DIFS™, Gen-3 HALO Clarity, and virtual clinic. |
| Nov 18 | Clinical case report | Positive | -1.9% | Single-patient case showed promising 15 mA device results without adverse events. |
| Nov 13 | Israel distribution deal | Positive | -7.1% | Exclusive Gen-2 SYNC distribution in Israel after regulatory approval. |
| Nov 05 | FDA Q-Submission accepted | Positive | -4.3% | FDA accepted Q-Submission for Gen-2 SYNC in Alzheimer’s and dementia. |
Recent history shows more price divergences than alignments on positive news, with three negative reactions versus two positive following generally favorable clinical and regulatory updates.
Over the past month, Nexalin reported several potentially positive milestones, including FDA acceptance of a Q-Submission for the Gen-2 SYNC console on November 5, 2025 and an exclusive Gen-2 SYNC distribution deal in Israel on November 13, 2025. A promising case report using its 15 mA device and a substantive FDA Q-Submission meeting for Alzheimer’s on December 3, 2025 furthered its clinical story. The current investor webinar invitation fits into this sequence of efforts to highlight technology, clinical evidence, and global expansion.
Market Pulse Summary
This announcement invites investors to a December 4 webinar focused on Nexalin’s proprietary Deep Intracranial Frequency Stimulation technology, Gen-3 HALO Clarity headset, and virtual clinic model within a $537 billion mental health market. In recent months, the company reported FDA Q-Submission progress and new international distribution, while its latest 10-Q noted continued losses and a going concern warning. Investors may watch how management addresses capital needs, clinical milestones, and commercialization plans during the session.
Key Terms
deep intracranial frequency stimulation medical
AI-generated analysis. Not financial advice.
HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Nexalin’s CEO Mark White, who will provide an inside look at Nexalin’s game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will detail the Company’s growing body of clinical evidence, including collaborations with leading institutions like UC San Diego, and share updates on the Gen-3 HALO™ Clarity headset and Virtual Clinic model—designed for scalable, at-home treatment. With regulatory approvals secured internationally and U.S. expansion underway, Nexalin is positioned at the forefront of a
To register for the free webinar, please visit: https://www.redchip.com/webinar/NXL/88925127595.
Questions can be pre-submitted to NXL@redchip.com or online during the live event.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic frequency-based medical technology to treat mental health issues. Evidence indicates Nexalin’s neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its Gen-2 and Gen-3 next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Israel, and Oman. Additional information about the Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2024 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
NXL@redchip.com
FAQ
When is Nexalin (NXL) hosting its investor webinar and who will present?
What technologies will Nexalin (NXL) discuss at the December 4, 2025 webinar?
How can investors register for Nexalin (NXL) webinar on December 4, 2025?
Will Nexalin (NXL) cover clinical evidence and partnerships during the December 4 webinar?
Does Nexalin (NXL) have regulatory approvals and are U.S. plans discussed in the webinar?
Will there be an opportunity to ask questions during the Nexalin (NXL) December 4 event?
